{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:08:07Z","timestamp":1762272487866,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Molecular detection of the BCR-ABL1 fusion transcripts is necessary for the genetic confirmation of a chronic myeloid leukemia diagnosis and for the risk classification of acute lymphoblastic leukemia. BCR-ABL1 mRNAs are usually identified using a conventional RT-PCR technique according to the BIOMED-1 method. In this study, we evaluated 122 BCR-ABL1-positive samples with the Q-LAMP assay to establish if this technology may represent a valid alternative to the qualitative BIOMED-1 PCR technique usually employed for the detection and the discrimination of the common BCR-ABL1 transcripts (p190 and p210 isoforms). We found a 100% concordance rate between the two methods. Specifically, the p190- and p210-positive samples were amplified by Q-LAMP with a median threshold time (Tt) of 26.70 min (range: 24.45\u201331.80 min) and 20.26 min (range: 15.25-34.57 min), respectively. A median time of 19.63 was observed in samples displaying both (e13a2\/e14a2) p210 isoforms. Moreover, the Q-LAMP assay allowed recognition of the BCR-ABL1 e13a2 and e14a2 isoforms (median Tts 18.48 for e13a2 vs. 26.08 min for e14a2; p &lt; 0.001). Finally, 20 samples harboring rare BCR-ABL1 isoforms (e1a3, e13a3, e14a3, and e19a2) were correctly identified by the Q-LAMP assay. We conclude that the Q-LAMP assay may represent a faster and valid alternative to the qualitative BIOMED-1 RT-PCR for the diagnosis at BCR-ABL1-positive leukemias, especially when samples are analyzed in centers with restricted resources and\/or limited technical expertise.<\/jats:p>","DOI":"10.3390\/ijms20246106","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T04:30:35Z","timestamp":1575433835000},"page":"6106","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias"],"prefix":"10.3390","volume":"20","author":[{"given":"Stefania","family":"Stella","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"},{"name":"Center of Experimental Oncology and Hematology, A.O.U. Policlinico-Vittorio Emanuele, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico Marco","family":"Gottardi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, A.O.U. San Luigi Gonzaga, 10043 Orbassano (Turin), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Favout","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, A.O.U. San Luigi Gonzaga, 10043 Orbassano (Turin), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6735-0038","authenticated-orcid":false,"given":"Eva","family":"Barragan Gonzalez","sequence":"additional","affiliation":[{"name":"Molecular Biology Unit, La Fe Universitary and Polytechnic Hospital, La Fe Health Research Institute, 46000 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santa","family":"Errichiello","sequence":"additional","affiliation":[{"name":"Centro Ingegeneria Genetica (CEINGE)\u2013Biotecnologie Avanzate, University Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Rita","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"},{"name":"Center of Experimental Oncology and Hematology, A.O.U. Policlinico-Vittorio Emanuele, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, A.O.U. San Luigi Gonzaga, 10043 Orbassano (Turin), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigia","family":"Luciano","sequence":"additional","affiliation":[{"name":"Hematology Unit, A.O.U. Federico II, University of Naples, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-158X","authenticated-orcid":false,"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplant, AOU Policlinico-Vittorio Emanuele, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Hematology Unit, A.O.U. Federico II, University of Naples, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrezia","family":"Pironi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, A.O.U. San Luigi Gonzaga, 10043 Orbassano (Turin), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sargas Simarro","sequence":"additional","affiliation":[{"name":"Molecular Biology Unit, La Fe Universitary and Polytechnic Hospital, La Fe Health Research Institute, 46000 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"},{"name":"Center of Experimental Oncology and Hematology, A.O.U. Policlinico-Vittorio Emanuele, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Izzo","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Biotechnology, University Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V80.12.2983.2983","article-title":"Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762)","volume":"80","author":"Westbrook","year":"1992","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s12185-017-2382-2","article-title":"10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation","volume":"107","author":"Fujimaki","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","article-title":"Imatinib mesylate in chronic myeloid leukemia: Frontline treatment and long-term outcomes","volume":"16","author":"Stagno","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Giallongo, C., Parrinello, N., Tibullo, D., La Cava, P., Romano, A., Chiarenza, A., Barbagallo, I., Palumbo, G.A., Stagno, F., and Vigneri, P. (2014). Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101848"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Preyer, M., Vigneri, P., and Wang, J.Y. (2011). Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017020"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2174\/1568009616666160105105857","article-title":"Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia","volume":"16","author":"Manzella","year":"2016","journal-title":"Curr. Cancer Drug Targ."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2353\/jmoldx.2009.090008","article-title":"A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: Diagnostic challenges in clinical laboratory practice","volume":"11","author":"Jinawath","year":"2009","journal-title":"J. Mol. Diagn. JMD"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12185-008-0031-5","article-title":"A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: Case report and review of the literature","volume":"87","author":"Fujisawa","year":"2008","journal-title":"Int. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.21873\/anticanres.13548","article-title":"Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report","volume":"39","author":"Massimino","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_14","first-page":"2648","article-title":"Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report","volume":"18","author":"Massimino","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V126.23.597.597","article-title":"Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC","volume":"126","author":"Bonifacio","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/1078-0432.CCR-17-0962","article-title":"High BCR-ABL\/GUS(IS) Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib","volume":"23","author":"Vigneri","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000492941","article-title":"Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph\u2019+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report","volume":"63","author":"Pirosa","year":"2018","journal-title":"Chemotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.21873\/anticanres.13130","article-title":"B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report","volume":"39","author":"Stella","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia","volume":"13","author":"Macintyre","year":"1999","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1093\/nar\/28.12.e63","article-title":"Loop-mediated isothermal amplification of DNA","volume":"28","author":"Notomi","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s12010-010-9088-8","article-title":"Applications of loop-mediated isothermal DNA amplification","volume":"163","author":"Fu","year":"2011","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nakao, R., Stromdahl, E.Y., Magona, J.W., Faburay, B., Namangala, B., Malele, I., Inoue, N., Geysen, D., Kajino, K., and Jongejan, F. (2010). Development of loop-mediated isothermal amplification (LAMP) assays for rapid detection of Ehrlichia ruminantium. BMC Microbiol., 10.","DOI":"10.1186\/1471-2180-10-296"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/jam.12290","article-title":"Developing a real-time quantitative loop-mediated isothermal amplification assay as a rapid and accurate method for detection of Brucellosis","volume":"115","author":"Soleimani","year":"2013","journal-title":"J. Appl. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.18632\/oncoscience.114","article-title":"Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology","volume":"2","author":"Spinelli","year":"2015","journal-title":"Oncoscience"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3324\/haematol.2011.056184","article-title":"A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms","volume":"97","author":"Minnucci","year":"2012","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/17474086.2013.826910","article-title":"Mutations and chromosomal rearrangements of JAK2: Not only a myeloid issue","volume":"6","author":"Salmoiraghi","year":"2013","journal-title":"Expert Rev. Hematol."},{"key":"ref_33","first-page":"234","article-title":"Development of new tools for molecular diagnosis of hematologic malignancies","volume":"40","author":"Salmoiraghi","year":"2016","journal-title":"Biochim. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14737140.2014.895669","article-title":"Current and future management of Ph\/BCR-ABL positive ALL","volume":"14","author":"Maino","year":"2014","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): An interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors","volume":"125","author":"Farina","year":"2019","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/24\/6106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:39:57Z","timestamp":1760189997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/24\/6106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":38,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["ijms20246106"],"URL":"https:\/\/doi.org\/10.3390\/ijms20246106","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2019,12,4]]}}}